TCM
BCRX icon

Tradewinds Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Tradewinds Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-750
Closed -$12K – 755
2021
Q2 		$12K Buy
+750
New +$10.2K ﹤0.01% 446

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Tradewinds Capital Management's BCRX Position: Q3 2021 in Review

Tradewinds Capital Management sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2021, closing a stake of 750 shares — an estimated $12K sold.

Tradewinds Capital Management first reported a position in BCRX in Q2 2021 and held it in 1 quarter. The position peaked at $12K in Q2 2021. 197 funds tracked by Wall St. Rank hold BCRX as of Q3 2021.

  • Tradewinds Capital Management reported no remaining BioCryst Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Tradewinds Capital Management sold 750 BioCryst Pharmaceuticals shares in Q3 2021, an estimated $12K.
  • Tradewinds Capital Management first reported a position in BioCryst Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Tradewinds Capital Management's BioCryst Pharmaceuticals position peaked at $12K in Q2 2021.
  • 197 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2021.

Based on Tradewinds Capital Management's 13F filing for Q3 2021, filed 4 Nov 2021.